化疗联合DC和CIK方案治疗非小细胞肺癌的临床疗效观察

目的：探讨化疗联合树突状细胞（DC）和细胞因子诱导的杀伤细胞（ELK）方案治疗非小细胞肺癌的临床疗效。方法：随机选取2008年10月份．2011年02月份因非小细胞肺癌就诊于我院进行治疗的患者120例，随机分为治疗组60例患者（采用化疗联合树突状细胞（DC）和细胞因子诱导的杀伤细胞（CIK方案治疗），对照组60例患者（采用常规化疗），统计两组患者的治疗效果以及生活质量情况，并对结果进行统计分析。结果：治疗组患者治疗总有效率为68．4％，生活质量提高率为88．4％，明显好于与对照组，经统计分析，P〈0．05，差异存在显著性。结论：化疗联合树突状细胞（DC）和细胞因子诱导的杀伤细胞（CIK）方案治疗非小细胞肺癌能够显著改善患者的生活质量，是治疗非小细胞肺癌的有效方法。

The Clinical Effect Observation of Chemotherapy Combined with DC and CIK for the Treatment of Non-small Cell Lung Cancer

Objective： To discuss the clinical effect of chemotherapy combined with dendritic cells （DC） and cytokine-induced killer cells （CIK） for the treatment of non-small cell lung cancer. Methods： From October, 2008 to February 2011, 120 patients with non-small cell lung cancer were randomly divided into treatment group （chemotherapy combined with dendritic cells （DC） and cytokine-induced killer cells （CIK） group, n=60）and control group （conventional chemotherapy group, n=60）. We summarized the curative effect and the quality of life of patients and made a statistical analysis for the results. Results： In the treatment group, the total effective rate was 68.4%, the improvement rate of the quality of life was 88.4%. It was significantly better when compared with the control group. After the statistical analysis, P〈0.05, there were significant differences. There was a significant difference in statistics. Conclusion： Chemotherapy combined with dendritic cells （DC） and cytokine-induced killer cells （CIK） for the treatment of non-small cell lung cancer can improve the quality of life for the patient. It is a effective method for the treatment of non-small cell lung cancer.